| Isatin-benzoazine molecular hybrids as potential antiproliferative agents: synthesis and in vitro pharmacological profiling HA Abdel-Aziz, WM Eldehna, AB Keeton, GA Piazza, AA Kadi, MW Attwa, ... Drug Design, Development and Therapy, 2333-2346, 2017 | 52 | 2017 |
| An LC–MS/MS method for rapid and sensitive high‐throughput simultaneous determination of various protein kinase inhibitors in human plasma AS Abdelhameed, MW Attwa, AA Kadi Biomedical Chromatography 31 (2), e3793, 2017 | 47 | 2017 |
| Metabolic stability assessment of new parp inhibitor talazoparib using validated lc–ms/ms methodology: In silico metabolic vulnerability and toxicity studies MW Attwa, AA Kadi, AS Abdelhameed, HA Alhazmi Drug design, development and therapy, 783-793, 2020 | 43 | 2020 |
| Detection and characterization of ponatinib reactive metabolites by liquid chromatography tandem mass spectrometry and elucidation of bioactivation pathways AA Kadi, HW Darwish, MW Attwa, SM Amer RSC advances 6 (76), 72575-72585, 2016 | 40 | 2016 |
| Reactive intermediates and bioactivation pathways characterization of avitinib by LC–MS/MS: in vitro metabolic investigation MW Attwa, AA Kadi, AS Abdelhameed Journal of Pharmaceutical and Biomedical Analysis 164, 659-667, 2019 | 39 | 2019 |
| Investigation of metabolic degradation of new ALK inhibitor: Entrectinib by LC-MS/MS MW Attwa, HW Darwish, HA Alhazmi, AA Kadi Clinica Chimica Acta 485, 298-304, 2018 | 39 | 2018 |
| Identification and characterization of in vivo, in vitro and reactive metabolites of vandetanib using LC–ESI–MS/MS MW Attwa, AA Kadi, HW Darwish, SM Amer, NS Al-Shakliah Chemistry Central Journal 12, 1-16, 2018 | 37 | 2018 |
| Identification and characterization of in vitro phase I and reactive metabolites of masitinib using a LC-MS/MS method: bioactivation pathway elucidation SM Amer, AA Kadi, HW Darwish, MW Attwa RSC advances 7 (8), 4479-4491, 2017 | 37 | 2017 |
| LC–MS/MS reveals the formation of iminium and quinone methide reactive intermediates in entrectinib metabolism: in vivo and in vitro metabolic investigation MW Attwa, AA Kadi, H Alrabiah, HW Darwish Journal of pharmaceutical and biomedical analysis 160, 19-30, 2018 | 36 | 2018 |
| Development of simultaneous determination of empagliflozin and metformin in human plasma using liquid chromatography–mass spectrometry and application to pharmacokinetics T Wattamwar, A Mungantiwar, S Halde, N Pandita European Journal of Mass Spectrometry 26 (2), 117-130, 2020 | 34 | 2020 |
| Identification and characterization of in silico, in vivo, in vitro, and reactive metabolites of infigratinib using LC-ITMS: Bioactivation pathway elucidation and in silico … NS Al-Shakliah, MW Attwa, AA Kadi, H AlRabiah RSC advances 10 (28), 16231-16244, 2020 | 34 | 2020 |
| LC–MS/MS method for the quantification of masitinib in RLMs matrix and rat urine: application to metabolic stability and excretion rate SM Amer, AA Kadi, HW Darwish, MW Attwa Chemistry Central Journal 11, 1-7, 2017 | 33 | 2017 |
| Liquid chromatography tandem mass spectrometry method for the quantification of vandetanib in human plasma and rat liver microsomes matrices: metabolic stability investigation SM Amer, AA Kadi, HW Darwish, MW Attwa Chemistry Central Journal 11, 1-8, 2017 | 33 | 2017 |
| Detection and characterization of olmutinib reactive metabolites by LC‐MS/MS: Elucidation of bioactivation pathways MW Attwa, AA Kadi, AS Abdelhameed Journal of Separation Science, 2019 | 32 | 2019 |
| A reliable and stable method for the determination of foretinib in human plasma by LC-MS/MS: application to metabolic stability investigation and excretion rate MW Attwa, AA Kadi, HW Darwish, SM Amer, H Alrabiah European Journal of Mass Spectrometry 24 (4), 344-351, 2018 | 32 | 2018 |
| LC-MS/MS reveals the formation of aldehydes and iminium reactive intermediates in foretinib metabolism: phase I metabolic profiling AA Kadi, SM Amer, HW Darwish, MW Attwa RSC advances 7 (58), 36279-36287, 2017 | 32 | 2017 |
| A highly efficient and sensitive LC‐MS/MS method for the determination of afatinib in human plasma: application to a metabolic stability study AA Kadi, AS Abdelhameed, HW Darwish, MW Attwa, NS Al‐Shakliah Biomedical Chromatography 30 (8), 1248-1255, 2016 | 32 | 2016 |
| Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma MW Attwa, AA Kadi, HW Darwish, AS Abdelhameed RSC advances 8 (70), 40387-40394, 2018 | 30 | 2018 |
| LC-ESI-MS/MS reveals the formation of reactive intermediates in brigatinib metabolism: elucidation of bioactivation pathways AA Kadi, MW Attwa, HW Darwish RSC advances 8 (3), 1182-1190, 2018 | 30 | 2018 |
| Liquid chromatographic-tandem mass spectrometric assay for simultaneous quantitation of tofacitinib, cabozantinib and afatinib in human plasma and urine MWAAHB Adnan A Kadi , Ali S Abdelhameed, Hany W Darwish Tropical Journal of Pharmaceutical Research, 2016 | 30 | 2016 |
Ali Saber AbdelhameedProfessor, College of Pharmacy, King Saud UniversityEmail verificata su ksu.edu.sa
